Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection

Inclusion Criteria: * Male and female over 18 years old (18 years inclusive). * Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen as diagnosed within 72 hours prior to randomization. * Expected to survive for at least 96 hours after study entry. * If patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence). * Subject or legally authorized representative understands and agrees to comply with planned study procedures. * Subject or legally authorized representative provides informed consent prior to initiation of any study procedures. Exclusion Criteria: * Women currently pregnant or breast-feeding. * Patients presenting acute impairment of renal function or nephrolithiasis. * Patients presenting hypercalcaemia and/or hypercalciuria * Patients presenting pseudohypoparathyroidism * Use of any vitamin D supplementation alone or in association at screening visit; * Use of any prohibited medication as detailed in the concomitant medication section * Patients with any sensitivity or allergy to any of the products used within this clinical trial. * Presence of any other condition or illness, which, in the opinion of the investigator, would interfere with optimal participation in the study.